FDA
-
-
-
-
-
-
-
BTIG Reiterates Neutral Rating on Insight Molecular Diagnostics Inc. (IMDX)
-
-
-
-
-
-
-
IMDX study shows GraftAssure assay outperforms standard rejection tests
-
-
-
-
-
-
-
iMDx hires Steven Tahmooressi as marketing VP ahead of 2026 launch
-
-
-
-
-
-
-
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
-
-
-
-
-
-
-
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

